- Home
- SKWD vs ZYME Comparison
SKWD vs ZYME Comparison
Compare SKWD & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SKWD | ZYME |
|---|---|---|
| Founded | 2007 | 2003 |
| Country | United States | United States |
| Employees | N/A | 264 |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.7B |
| IPO Year | 2022 | 2022 |
Fundamental Metrics
Financial Performance| Metric | SKWD | ZYME |
|---|---|---|
| Price | $50.05 | $22.88 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 11 |
| Target Price | ★ $64.63 | $38.90 |
| AVG Volume (30 Days) | 314.9K | ★ 610.6K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 41.81 | 33.33 |
| EPS | ★ 1.09 | N/A |
| Revenue | ★ $1,416,541,000.00 | $105,965,000.00 |
| Revenue This Year | $29.54 | $183.10 |
| Revenue Next Year | $12.64 | N/A |
| P/E Ratio | $46.61 | ★ N/A |
| Revenue Growth | 23.16 | ★ 38.87 |
| 52 Week Low | $40.60 | $11.86 |
| 52 Week High | $59.79 | $29.75 |
Technical Indicators
Market Signals| Indicator | SKWD | ZYME |
|---|---|---|
| Relative Strength Index (RSI) | 65.27 | 36.59 |
| Support Level | $43.39 | $22.28 |
| Resistance Level | $50.28 | $23.66 |
| Average True Range (ATR) | 1.51 | 0.92 |
| MACD | 0.59 | -0.15 |
| Stochastic Oscillator | 82.97 | 17.07 |
Price Performance
Historical ComparisonAbout SKWD Skyward Specialty Insurance Group Inc.
Skyward Specialty Insurance Group Inc is a specialty insurance company that offers a suite of specialized insurance solutions across specialty property and casualty markets on a non-admitted and admitted basis. Its portfolio of insurance offerings covers a wide variety of risks, including general liability, commercial auto, group accident and health, property, agriculture, credit, surety, and workers' compensation, among others. Geographically, the group mainly operates in the United States.
About ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.